

Eff. Date: 1 June 2023

Version: 2.1 IFU: CD43 ILM6693

CD 43 clone DF-T1

Instructions for Use

Specification:

The anti-CD43 antibody recognizes a cell surface glycoprotein of 95/115/135kDa (depending upon the extent of glycosylation), identified as CD43. 70-90% of T-cell lymphomas and from 22-37% of B-cell lymphomas express CD43. No reactivity has been observed with reactive B-cells. So, a B-lineage population that co-expresses CD43 is highly likely to be a malignant lymphoma, especially a low-grade lymphoma, rather than a reactive B-cell population. When CD43 antibody is used in combination with anti-CD20, effective immunophenotyping of the lymphomas in formalin-fixed tissues can be obtained. Co-staining of a lymphoid infiltrate with anti-CD20 and anti-CD43 argues against a reactive process and favors a diagnosis of lymphoma.

Availability:

Catalog No.	Contents	Volume
ILM6693-C01	CD43	0,1 ml concentrate
ILM6693-C05	CD43	0,5 ml concentrate
ILM6693-C1	CD43	1.0 ml concentrate

Intended use: For Research Use Only

Reactivity: Human

Clone: DF-T1

Species of origin: Mouse

Isotype: IgG1, K

Control Tissue: Tonsil

Staining: Membranous

Immunogen: KG1 cells (myoblast cell line)

Presentation: Bioreactor Concentrate with 0.05% Azide

Application and suggested dilutions:

Pretreatment: Heat induced epitope retrieval in 10 mM citrate buffer, pH6.0, or in 50 mM Tris buffer pH9.5, for 20 minutes is required for IHC staining on formalin-fixed, paraffin embedded tissue sections.

- Immunohistochemical staining of formalin-fixed, paraffin embedded tissue section (dilution up to 1:100-1:200)
- Western blotting (dilution 1:100-1:200)


The optimal dilution for a specific application should be determined by the investigator.

Note: Dilution of the antibody in 10% normal goat serum followed by a goat anti-mouse secondary antibody-based detection is recommended.

Storage & Stability: Store at 2-8 °C. Do not use after expiration date printed on the vial.

References:

- 1) Leong A, Cooper K, Leong F. London: Oxford University Press; 1999. p. 91-2.
- 2) Stross WP, Warnke RA, Flavell DJ, Flavell SU, Simmons D, Gatter KC, et al. J Clin Pathol 1989; 42:953-61.
- 3) de Smet W, Walter H, van Hove L.. Immunology 1993;79:46-54.



WellMed BV, Delta 52, 6825 MS, Arnhem, The Netherlands

